Telix posts US$247 million Q2 revenue, lifts FY 2026 outlook to more than US$1 billion
AI Market Summary
Telix reported Q2 FY2026 revenue of US$247M (+7% QoQ, +21% YoY) and lifted FY2026 revenue and other income expectations to exceed US$1B, supported by strong PSMA imaging demand and a US$40M nonrefundable Regeneron payment. FDA alignment to advance ProstACT Phase 3 (Part 2) and a Pixclara® PDUFA date add regulatory visibility, while refinancing extends maturities and improves flexibility.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.92%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Telix reported FY 2026 Q2 revenue of US$247 million, up 7% quarter over quarter and 21% year over year, and raised its full-year revenue outlook to more than US$1 billion. The company said the U.S. FDA confirmed its ProstACT Global Phase 3 study can move into Part 2 in the U.S., and set a PDUFA goal date of September 11, 2026 for Pixclara®. Telix also announced a strategic collaboration with Regeneron that includes an initial nonrefundable payment of US$40 million.
